ClinicalTrials.gg
Enrolling by invitationNCT07094776PCOSMG53Updated Aug 6, 2025

Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study

An observational study in Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Syndrome, sponsored by Havva Betül Bacak. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Havva Betül Bacak · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
128
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Polycystic Ovary Syndrome with a site in Turkey — 14 open to participants now, 15 under way, none of them phase 3. Polycystic Ovary Syndrome · Turkey.

Planned enrollment
15th of 43
128 · median 90
Started
2025
with 6 others
Observational
43 of 72
4 open now
Primary completion
2025-08
later than 2 of 14 live
Registered
50th of 72
by date

Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, this one is the 15th largest by planned enrollment of the 43 observational ones that give a count, is one of 7 that started in 2025, is one of 43 observational ones, reaches primary completion later than 2 of the 14 other live ones, and was the 50th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

14 of the 72 studies in Polycystic Ovary Syndrome with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Polycystic Ovary Syndrome with a site in Turkey, or all of them as a file.
02

Study summary

Purpose of the Study:

This study is being conducted to examine a protein called MG53 (also known as TRIM72) in women with polycystic ovary syndrome (PCOS). MG53 is involved in cell membrane repair and may play a role in insulin resistance, which is common in PCOS.

Study Procedures:

Women between 18 and 45 years of age will be invited to participate. The study population will include both women diagnosed with PCOS and healthy controls. A single blood sample (approximately 5 mL) will be collected from each participant. MG53 levels will be measured using an ELISA laboratory assay.

Significance of the Study:

Analysis of MG53 levels in relation to hormonal and metabolic markers may help determine whether MG53 is associated with insulin resistance and other characteristics of PCOS.

Read the detailed description

Background:

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age and is often associated with insulin resistance and metabolic disturbances. MG53 (TRIM72) is a membrane repair protein that has been shown in some experimental studies to affect insulin signaling and glucose metabolism.

Rationale:

Because insulin resistance is a key feature of PCOS, investigating MG53 levels in women with PCOS may provide new insights into the pathophysiology of the syndrome. Understanding whether MG53 is elevated and how it correlates with metabolic and hormonal parameters could lead to new diagnostic or therapeutic approaches in the future.

Study Design:

This is an observational, cross-sectional, single-center study. A total of 128 participants will be included: 64 women diagnosed with PCOS (based on the Rotterdam criteria) and 64 healthy women as controls.

Procedures:

Each participant will undergo a single blood draw (approximately 5 mL). MG53 levels will be measured using an ELISA method. Routine laboratory markers associated with PCOS (including HOMA-IR, BMI, LH/FSH ratio, total testosterone, DHEA-S, SHBG, free androgen index, triglycerides, HDL, LDL, and total cholesterol) will also be recorded from standard clinical evaluations.

Data Analysis:

Statistical analysis will include normality testing (Kolmogorov-Smirnov), comparison of groups (Student's t-test or Mann-Whitney U test), and correlation analyses (Pearson or Spearman). Sample size was calculated using G*Power software.

Outcome Measures:

The primary outcome is the serum level of MG53. Secondary outcomes include the correlation between MG53 levels and metabolic/hormonal parameters.

Significance:

This study does not involve any investigational drug or device and poses minimal risk to participants. The findings may contribute to the understanding of metabolic pathways involved in PCOS.

03

Conditions studied

  • Polycystic Ovary Syndrome (PCOS)
  • Insulin Resistance Syndrome

Keywords

  • MG53
  • TRIM72
  • Polycystic Ovary Syndrome
  • PCOS
  • Insulin Resistance
  • Metabolic Markers
  • ELISA
  • Cross-Sectional Study
  • HOMA-IR
  • SHBG
  • Androgen Index
  • Lipid Profile
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of women aged 18 to 45 years. One group includes women diagnosed with polycystic ovary syndrome (PCOS) based on the Rotterdam criteria, and the other group includes healthy female controls without PCOS or other chronic conditions. All participants will provide informed consent before enrollment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants aged 18 to 45 years
  • Diagnosed with polycystic ovary syndrome (PCOS) according to Rotterdam criteria or healthy controls without PCOS
  • Able and willing to provide

Exclusion criteria

Exclusion Criteria:

Currently pregnant

  • Presence of chronic systemic disease
  • Use of metformin or any hormonal treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
128 participants (estimated)
Patient registry
No

Groups and cohorts

  • PCOS Group

    Women aged 18-45 years diagnosed with polycystic ovary syndrome (PCOS) based on Rotterdam criteria. A single blood sample is collected for MG53 and routine metabolic markers. No intervention is applied.

    Other: No intervention (observational study)

  • Healthy Controls

    Women aged 18-45 years without PCOS or other chronic conditions. A single blood sample is collected for MG53 and routine metabolic markers. No intervention is applied.

    Other: No intervention (observational study)

Interventions

  • OtherNo intervention (observational study)

    This is an observational study. No drugs, devices, or treatments are administered. Participants only provide a single blood sample for MG53 and routine metabolic measurements.

06

What researchers measure

Primary outcomes

  1. Serum MG53 level

    Serum MG53 levels measured by ELISA in women with PCOS and healthy controls. Time Frame: At the time of blood draw (single measurement at enrollment)

    Time frame: Baseline (single time point at enrollment)

Secondary outcomes

  1. Correlation between MG53 levels and insulin resistance (HOMA-IR)

    Association between MG53 levels and HOMA-IR index derived from fasting glucose and insulin.

    Time frame: At the time of blood draw (single measurement at enrollment)

  2. Correlation between MG53 levels and BMI

    Association between MG53 levels and body mass index (BMI).

    Time frame: At the time of blood draw (single measurement at enrollment)

  3. Correlation between MG53 levels and hormonal parameters

    Association between MG53 levels and LH/FSH ratio, total testosterone, DHEA-S, SHBG, and free androgen index.

    Time frame: At the time of blood draw (single measurement at enrollment)

  4. Correlation between MG53 levels and lipid parameters

    Association between MG53 levels and triglycerides, HDL-cholesterol, LDL-cholesterol, and total cholesterol.

    Time frame: At the time of blood draw (single measurement at enrollment)

07

Study locations

1 site
  • University of Health Sciences, Gaziosmanpaşa Training and Research Hospital
    Gaziosmanpaşa, Istanbul 34255, Turkey (Türkiye)
08

References and documents

Publications

  • Coskun ES, Gencer FK, Salman S, Nurlu N, Bacak HB, Kumbasar S, Timur GY, Celikoglu E, Unlu S, Tunccag F, Guven R. Decreased serum MG53 levels are associated with SHBG and androgen excess in women with polycystic ovary syndrome. Sci Rep. 2026 Apr 13;16(1):15753. doi: 10.1038/s41598-026-48800-z. PubMed 41974999 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this study does not include a plan for public data sharing, and participant consent for data sharing has not been obtained.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Aug 2025, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Jul 30, 2025
StartActual
Jun 18, 2025
Primary completionEst.
Aug 20, 2025
CompletionEst.
Aug 20, 2025
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07094776
Lead sponsor
Havva Betül Bacak
Responsible party
Havva Betül Bacak (M.D, Gaziosmanpasa Research and Education Hospital) — Sponsor-investigator
First posted
Jul 30, 2025
Start date
Jun 18, 2025
Primary completion
Aug 20, 2025 (estimated)
Completion
Aug 20, 2025 (estimated)
Last update
Aug 6, 2025

Study contacts

Enes S Coşkun, M.D.
principal investigator · University of Health Sciences, Gaziosmanpaşa Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion